Inovio announced last week that it has dosed the first participant in a Phase 2 study of its INO-4700 DNA vaccine against MERS. The multicenter trial—funded by the Coalition for Epidemic Preparedness Innovations (CEPI)—will involve approximately 500 healthy adults in Jordan and Lebanon.
According to the press release, Inovio and CEPI plan to make a stockpile of INO-4700 “available for emergency use as soon as possible following Phase 2 testing.”